Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Cited by (1,000)

Items 101–200 of 1,000

1. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
   Yuxin Lin, Xian Wang, Hongchuan Jin · 2014 · Europe PMC (PubMed Central)
2. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
   Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, Jan Nyrop Jakobsen, Karin de Stricker, Morten Grauslund, Jens Benn Sørensen · 2019 · Cancers
3. Reprogramming the immunological microenvironment through radiation and targeting Axl
   Todd Anthony Aguilera, Marjan Rafat, Laura Castellini, Hussein Shehade, Mihalis S. Kariolis, Angela Bik‐Yu Hui, Henning Stehr, Rie von Eyben, Dadi Jiang, Lesley G. Ellies et al. · 2016 · Nature Communications
4. AXL kinase as a novel target for cancer therapy
   Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balázs Halmos · 2014 · Oncotarget
5. Axl as a mediator of cellular growth and survival
   Haley D. Axelrod, Kenneth J. Pienta · 2014 · Oncotarget
6. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
   Cabanos, Heidie Frisco, Hata, Aaron N. · 2021 · Cancers
7. MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
   Kazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, Kuniko Matsuda, Akihiko Miyanaga, Hideaki Mizutani, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Akihiko Gemma · 2013 · Molecular Cancer Therapeutics
8. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
   Amit J. Sabnis, Trever Grant Bivona · 2019 · Trends in Molecular Medicine
9. Current Landscape of Targeted Therapy in Lung Cancer
   Manasi K. Mayekar, Trever Grant Bivona · 2017 · Clinical Pharmacology & Therapeutics
10. Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019)
    Parth Bhatia, Vrinda Sharma, Ozair Alam, Ajay Manaithiya, Perwaiz Alam, Kahksha, Md Tauquir Alam, Mohd Imran · 2020 · European Journal of Medicinal Chemistry
11. AXL-Driven EMT State as a Targetable Conduit in Cancer
    Jane Antony, Ruby Yun‐Ju Huang · 2017 · Cancer Research
12. Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression
    Hao Liu, Danxiu Li, Lina Sun, Hongqiang Qin, Ahui Fan, Lingnan Meng, Ramona Graves‐Deal, Sarah E. Glass, Jeffrey L. Franklin, Qi Liu et al. · 2022 · Molecular Cancer
13. Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
    Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura et al. · 2017 · Cancer Research
14. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
    Zachary Alan Yochum, Jessica Cades, Hailun Wang, Suman Chatterjee, Brian Wesley Simons, James P. O’Brien, Susheel K. Khetarpal, Ghali Lemtiri-Chlieh, Kayla V. Myers, Eric H.‐B. Huang et al. · 2018 · Oncogene
15. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
    Nilsson, Monique B., Sun, Huiying, Robichaux, Jacqulyne, Pfeifer, Matthias, McDermott, Ultan, Travers, Jon, Diao, Lixia, Xi, Yuanxin, Tong, Pan, Shen, Li et al. · 2020 · Science Translational Medicine
16. A framework for understanding and targeting residual disease in oncogene-driven solid cancers
    Trever Grant Bivona, Robert Charles Doebele · 2016 · Nature Medicine
17. Current Advances in the Treatment of BRAF-Mutant Melanoma
    Hima Milan Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Long Yuan, Samar Alanazi, Joan T. Garrett · 2020 · Cancers
18. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
    Sau-Chi Betty Yan, Victoria L. Peek, Rose T. Ajamie, Sean G. Buchanan, Jeremy Richard Graff, Steven A. Heidler, Yu‐Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason R. Manro et al. · 2012 · Investigational New Drugs
19. A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
    Frederick Hugh Wilson, Cory M. Johannessen, Federica Piccioni, Pablo Tamayo, Jong Wook Kim, Eliezer M. Van Allen, Steven M. Corsello, Marzia Capelletti, Antonio Calles, Mohit Butaney et al. · 2015 · Cancer Cell
20. The Receptor Tyrosine Kinase AXL in Cancer Progression
    Erinn B. Rankin, Amato J. Giaccia · 2016 · Cancers
21. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung
    Sehui Kim, Jaemoon Koh, Moon‐Young Kim, Dohee Kwon, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung · 2016 · Human Pathology
22. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
    Sima Lev · 2020 · Biochemical Society Transactions
23. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
    I-K Park, Bethany L. Mundy-Bosse, Susan P. Whitman, X Zhang, S L Warner, David J. Bearss, William G. Blum, Guido Marcucci, Michael A. Caligiuri · 2015 · Leukemia
24. Synergistic Prevention of Biofouling in Seawater Desalination by Zwitterionic Surfaces and Low‐Level Chlorination
    Rong Yang, Hongchul Jang, Roman Stocker, Karen K. Gleason · 2013 · Advanced Materials
25. ERK1/2 Blockade Prevents Epithelial–Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition
    Janine M. Buonato, Matthew J. Lazzara · 2013 · Cancer Research
26. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
    Miles Aaron Miller, Madeleine J. Oudin, Ryan Joseph Sullivan, Stephanie J. Wang, Aaron S. Meyer, Hyungsoon Im, Dennie Tompers Frederick, Jenny Tadros, Linda Gay Griffith, Hakho Lee et al. · 2016 · Cancer Discovery
27. Mechanisms of lapatinib resistance in HER2-driven breast cancer
    Valentina D’Amato, Lucia Raimondo, Luigi Formisano, Mario Giuliano, Sabino De Placido, Roberta Rosa, Roberto Bianco · 2015 · Cancer Treatment Reviews
28. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
    Elie A. Traer, Jacqueline Martinez, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer B. Dunlap, Isabel A. English, Tibor J. Kovacsovics, Jeffrey W Tyner, Melissa Hirose Wong, Brian J. Druker · 2016 · Cancer Research
29. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
    Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, Cristina Teixidó, Niki Karachaliou, Martin H. Pedersen, Josep Castellví, Mónica Garzón, Carles Codony, Jordi Codony‐Servat et al. · 2017 · Nature Communications
30. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer
    Kathleen F. Ludwig, Wenting Du, Noah B. Sorrelle, Katarzyna Wnuk-Lipińska, Mary Topalovski, Jason E. Toombs, Victoria H. Cruz, Shinichi Yabuuchi, N.V. Rajeshkumar, Anirban Maitra et al. · 2017 · Cancer Research
31. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
    Cortot, Alexis B., Jänne, Pasi A. · 2014 · European Respiratory Review
32. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
    Erika Martinelli, Floriana Morgillo, Teresa Troiani, Fortunato Ciardiello · 2016 · Cancer Treatment Reviews
33. Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
    Keith Michael Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, Priscilla M. Zhang, Andrew David Redfern, Lisa M. Stuart, Gregory J. Goodall, Peter J. Leedman · 2013 · Molecular Cancer Therapeutics
34. Inactivation of Capicua drives cancer metastasis
    Ross A. Okimoto, Frank Breitenbuecher, Victor R. Olivas, Wei Wu, Beatrice Gini, Matan Hofree, Saurabh Asthana, Gorjan Hrustanovic, Jennifer Flanagan, Asmin Tulpule et al. · 2016 · Nature Genetics
35. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy
    Yemsratch T. Akalu, Carla Vanina Rothlin, Sourav Ghosh · 2017 · Immunological Reviews
36. Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
    Margaret Soucheray, Marzia Capelletti, Inés Pulido, Yanan Kuang, Cloud Peter Paweletz, Jeffrey H. Becker, Eiki Kikuchi, Chunxiao Xu, Tarun B. Patel, Fátima Al‐Shahrour et al. · 2015 · Cancer Research
37. Seipin: from human disease to molecular mechanism
    Bethany R. Cartwright, Joel M. Goodman · 2012 · Journal of Lipid Research
38. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
    Toshimitsu Yamaoka, Motoi Ohba, Tohru Ohmori · 2017 · International Journal of Molecular Sciences
39. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer
    Lidia Bosurgi, Jochem H. Bernink, Víctor D. Cuevas, Nicola Gagliani, Leonel D. Joannas, Edward T. Schmid, Carmen Jane Booth, Sourav Ghosh, Carla Vanina Rothlin · 2013 · Proceedings of the National Academy of Sciences
40. Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation
    Cristina Bárcena, Milica Stefanović, Anna Tutusaus, Leonel D. Joannas, Anghara Menéndez, Carmen García‐Ruiz, Pau Sancho‐Bru, Montserrat Marı́, Joan Caballería, Carla Vanina Rothlin et al. · 2015 · Journal of Hepatology
41. AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
    Wilson, Catherine, Ye, Xiaofen, Pham, Thinh, Lin, Eva, Chan, Sara, McNamara, Erin, Neve, Richard M., Belmont, Lisa, Koeppen, Hartmut, Yauch, Robert L. et al. · 2014 · Cancer Research
42. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
    Cun Wang, Haojie Jin, Ning Wang, Shao‐Hua Fan, Yanyan Wang, Yurong Zhang, Wei Lin, Xuemei Tao, Dishui Gu, Fangyu Zhao et al. · 2016 · Theranostics
43. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
    Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David M. Briere, Jill F. Hallin, Pedro Pablo Lopez-Casas et al. · 2017 · Clinical Cancer Research
44. Personalized therapy for lung cancer: striking a moving target
    Suchita Pakkala, Suresh S. Ramalingam · 2018 · JCI Insight
45. The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
    Juliano D. Paccez, Matjaž Vogelsang, Mohamed Iqbal Parker, Luiz Fernando Zerbini · 2013 · International Journal of Cancer
46. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets
    Renata Ferrarotto, Yoshitsugu Mitani, Daniel James McGrail, Kaiyi Li, Tatiana V. Karpinets, Diana Bell, Steven Jay Frank, Xingzhi Song, Michael Elliot Kupferman, Bin Liu et al. · 2020 · Clinical Cancer Research
47. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
    CATHERINE A. WILSON, Katrina Nicholes, Daisy J. Bustos, Eva Lin, Qinghua Song, Jean-Philippe Stéphan, Donald S. Kirkpatrick, Jeff Settleman · 2014 · Oncotarget
48. Lung Cancer Biomarkers: Present Status and Future Developments
    Philip T. Cagle, Timothy Craig Allen, Randall J. Olsen · 2013 · Archives of Pathology & Laboratory Medicine
49. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation
    Carlos E. Stahlhut, Frank John Slack · 2015 · Cell Cycle
50. MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
    Jin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Tae Won Kim, Eun Kyung Choi, Seon-Joo Yoon, Bu Man Park, Eunhye Park, Jong Hwan Bae, Chang‐Min Choi et al. · 2013 · Cancer Research
51. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
    Mihalis S. Kariolis, Yu Rebecca Miao, Douglas S Jones, Shiven Kapur, Irimpan I. Mathews, Amato J. Giaccia, Jennifer R. Cochran · 2014 · Nature Chemical Biology
52. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
    Ki Hyeong Lee · 2017 · Pharmacology & Therapeutics
53. De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients
    David Akhavan, Alexandra L. Pourzia, Alex A. Nourian, Kevin J. Williams, David A. Nathanson, Ivan Babić, Genaro R. Villa, Kazuhiro Tanaka, Ali Nael, Huijun Yang et al. · 2013 · Cancer Discovery
54. The emergence of drug resistance to targeted cancer therapies: Clinical evidence
    Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos · 2019 · Drug Resistance Updates
55. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
    Jordi Bertrán-Alamillo, Valérie Cattan, Marie Schoumacher, Jordi Codony‐Servat, Ana A. Giménez-Capitán, Frederique Cantero, Mike F. Burbridge, Sonia Rodríguez, Cristina Teixidó, Ruth Ann Roman et al. · 2019 · Nature Communications
56. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
    Jordi Remón, Teresa Morán, Margarita Majem, Noemı́ Reguart, Elsa Dalmau, Diego Márquez-Medina, PILAR LIANES · 2013 · Cancer Treatment Reviews
57. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
    Xueli Tian, Tingxuan Gu, Mee‐Hyun Lee, Zigang Dong · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
58. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
    Joel W. Neal, Suzanne Eleanor Dahlberg, Heather A. Wakelee, Seena C. Aisner, Michaela Bowden, Ying Huang, David Paul Carbone, Gregory James Gerstner, Rachel E. Lerner, Jerome L Rubin et al. · 2016 · The Lancet Oncology
59. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
    Marie Schoumacher, Mike F. Burbridge · 2017 · Current Oncology Reports
60. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies
    Jun He, Zejing Qiu, Jingjing Fan, Xiaohong Xie, Qinsong Sheng, Xinbing Sui · 2024 · Signal Transduction and Targeted Therapy
61. LAMC2 enhances the metastatic potential of lung adenocarcinoma
    Yong Wha Moon, Guanhua Rao, Junghoon Kim, Hyo Sup Shim, K-S Park, Steven S. An, Boyng Joo Kim, P. S. Steeg, Sami Sarfaraz, L Changwoo Lee et al. · 2015 · Cell Death and Differentiation
62. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Melissa Lynne Johnson, Helena Alexandra Yu, Eric M. Hart, Bing Bing Weitner, ALFRED W. RADEMAKER, Jyoti D. Patel, Mark G. Kris, Gregory J. Riely · 2015 · Journal of Clinical Oncology
63. G protein-coupled receptors as promising cancer targets
    Ying Liu, Su An, Richard John Ward, Yang Yang, Xiao‐Xi Guo, Wei Li, Tian‐Rui Xu · 2016 · Cancer Letters
64. EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
    Niki Karachaliou, Manuel Fernández-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell · 2018 · Translational Cancer Research
65. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
    Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
66. Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
    Salt, Megan B., Bandyopadhyay, Sourav, McCormick, Frank · 2014 · Cancer Discovery
67. Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
    Maurizio Scaltriti, Moshe Elkabets, Jose M Baselga · 2016 · Clinical Cancer Research
68. SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer
    Della Corte, Carminia Maria, Bellevicine, Claudio, Vicidomini, Giovanni, Vitagliano, Donata, Malapelle, Umberto, Accardo, Marina, Fabozzi, Alessio, Fiorelli, Alfonso, Fasano, Morena, Papaccio, Federica et al. · 2015 · Clinical Cancer Research
69. AXL in cancer: a modulator of drug resistance and therapeutic target
    Yaoxiang Tang, Hongjing Zang, Qiuyuan Wen, Songqing Fan · 2023 · Journal of Experimental & Clinical Cancer Research
70. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
    Katherine R. Amato, Shan Wang, Li Tan, Andrew K. Hastings, Wenqiang Song, Christine Marie Lovly, Catherine Belle Meador, Fei Ye, Lu Wang, Justin Micah Balko et al. · 2016 · Cancer Research
71. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer
    Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu et al. · 2020 · Clinical Cancer Research
72. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
    Jeong Eun Lee, Hee Sun Park, Dahye Lee, Geon Yoo, Tackhoon Kim, Haeyon Jeon, Min‐Kyung Yeo, Choong Sik Lee, Jae Young Moon, Sung Soo Jung et al. · 2016 · Biochemical and Biophysical Research Communications
73. ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
    D N Debruyne, Namrata Bhatnagar, B Sharma, William Luther, N F Moore, NK Cheung, Nathanael S. Gray, R E George · 2015 · Oncogene
74. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
    Toni Michel Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Hannah E. Pearson, Harsh Bahrar, Tyler L. Fowler, Bryan P. Bednarz et al. · 2015 · Clinical Cancer Research
75. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer
    Jane Antony, Tuan Zea Tan, Zoë L Kelly, Jeffrey J. H. Low, Mahesh Arjandas Choolani, Chiara Recchi, Hani Gabra, Jean Paul Thiery, Ruby Yun‐Ju Huang · 2016 · Science Signaling
76. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
77. Molecular insights of Gas6/TAM in cancer development and therapy
    Guiling Wu, Zhiqiang Ma, Wei Hu, Dongjin Wang, Bing Gong, Chongxi Fan, Shuai Jiang, Tian Xiang Li, Jianyuan Gao, Yang Yang · 2017 · Cell Death and Disease
78. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
    Jiaojiao Yu, Dandan Zhou, Xiaoxiao Yang, Bing Cui, Fengwei Tan, Junjian Wang, Ke Li, Shuang Shang, Cheng Zhang, Xiaoxi Lv et al. · 2020 · Nature Communications
79. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
    Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto et al. · 2020 · Nature Communications
80. Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation
    Hyeong Ryul Kim, Woo Sung Kim, Yun Jung Choi, Chang‐Min Choi, Jin Kyung Rho, Jae Cheol Lee · 2013 · Molecular Oncology
81. Signaling cross-talk in the resistance to HER family receptor targeted therapy
    Hirohito Yamaguchi, S.H. Chang, J L Hsu, Mien‐Chie Hung · 2013 · Oncogene
82. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer
    Bihui Cao, Manting Liu, Lu Wang, Kangshun Zhu, Mingyue Cai, Xiaopei Chen, Yunfei Feng, Shuo Yang, Shengyu Fu, Cheng Zhi et al. · 2022 · Nature Communications
83. AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
    Philip D. Dunne, Darragh G. McArt, Jaine K. Blayney, Murugan Kalimutho, Samanda Greer, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Maurice Bernard Loughrey et al. · 2013 · Clinical Cancer Research
84. The RTK Interactome: Overview and Perspective on RTK Heterointeractions
    Michael D. Paul, Kalina A. Hristova · 2018 · Chemical Reviews
85. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    Jing Gao, Hao-Ran Li, C. Jin, Jingwei Jiang, Jian‐Yong Ding · 2019 · Clinical & Translational Oncology
86. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
    Kang-Seo Park, Mark A. Raffeld, Yong Wha Moon, Liqiang Xi, Caterina Bianco, Trung C. Pham, Liam C. Lee, Tetsuya Mitsudomi, Yasushi Yatabe, Isamu Okamoto et al. · 2014 · Journal of Clinical Investigation
87. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
    Qiang Zuo, Jing Liu, Liping Huang, Yifei Qin, Teresa S. Hawley, Claire Seo, Glenn T Merlino, Yanlin Yu · 2018 · Oncogene
88. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Yasir Y. Elamin, Jacqulyne Ponville Robichaux, Brett W. Carter, Mehmet Altan, Hai Thanh Tran, Don Lynn Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. L. Lam, Xiuning Le et al. · 2022 · Cancer Cell
89. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
    Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, Benny Zhitomirsky, Yaara Oren, Sara K. Oster, Moshit Lindzen, Saptaparna Mukherjee, Rainer D. Will, Soma Ghosh et al. · 2022 · Cancer Discovery
90. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Kristine Raaby Jakobsen, Christina Demuth, Boe Sandahl Sørensen, Anders Lade Nielsen · 2016 · Translational Lung Cancer Research
91. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
    Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Valeria Smiroldo, M. Picciotto, Mariangela Zanghì, Christian Diego Rolfo, Vincenzo Adamo · 2017 · Critical Reviews in Oncology/Hematology
92. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
    Jing Wei, Huiyan Sun, Aimei Zhang, Xuejie Wu, Yuxiang Li, Jiawei Liu, Yanting Duan, Fengjun Xiao, Hua Wang, Ming Lv et al. · 2018 · Cellular Immunology
93. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
    Il‐Kyoo Park, Anjali Mishra, Jason Claud Chandler, Susan P. Whitman, Guido Marcucci, Michael A. Caligiuri · 2013 · Blood
94. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
    Koichi Azuma, Akihiko Kawahara, Kahori Sonoda, Kazutaka Nakashima, Kousuke Tashiro, Kosuke Watari, Hiroto Izumi, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono et al. · 2014 · Oncotarget
95. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
    Mihalis S. Kariolis, Yu Rebecca Miao, Anh N. Diep, Shannon E. Nash, Monica M. Olcina, Dadi Jiang, Douglas S. Jones, Shiven Kapur, Irimpan I. Mathews, Albert C. Koong et al. · 2016 · Journal of Clinical Investigation
96. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
    Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia A. Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, César A. Moran, Yukie Kashima, Thiruvengadam Arumugam et al. · 2023 · Cancer Cell
97. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
    Wilhem Leconet, Christel Larbouret, Thierry Chardès, Gaëlle Thomas, Madeline Neiveyans, Muriel Busson, Marta Jarlier, Nina Radosevic‐Robin, Martine Pugnière, Florence Bernex et al. · 2013 · Oncogene
98. Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
    Takeshi Yoshida, Guolin Zhang, Matthew A. Smith, Alex S. Lopez, Yun Bai, Jiannong Li, Bin Fang, John M. Koomen, Bhupendra Rawal, Kate J. Fisher et al. · 2014 · Clinical Cancer Research
99. Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
    Mikaella Vouri, David R. Croucher, Sean P. Kennedy, Q An, Geoffrey John Pilkington, Sassan Hafizi · 2016 · Oncogenesis
100. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
     Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2021 · Cancers